UB-612

Source: Wikipedia, the free encyclopedia.

UB-612
Vaccine description
TargetSARS-CoV-2
Vaccine typePeptide subunit
Clinical data
Routes of
administration
Intramuscular
Identifiers
DrugBank

UB-612 is a COVID-19 vaccine candidate developed by United Biomedical, Inc. Asia [zh], Vaxxinity (formerly known as COVAXX), and DASA.[1] It is a peptide vaccine.[2][3]

Technology

UB-612 is a peptide vaccine incorporating multiple epitopes, including the spike protein receptor binding domain as well as other virus structural proteins.[1][3] The spike protein peptide is fused to an Fc domain of single-chain IgG1, and the other six peptides are derived from highly conserved sequences from the spike, nucleocapsid, and membrane proteins of SARS-CoV-1 and SARS-CoV-2. It also contains a proprietary UBITh1 peptide derived from the measles virus fusion protein, CpG oligonucleotides, and aluminum phosphate adjuvant to improve the immune response. It is produced in CHO cells.[2]

Clinical trials

In September 2020, UB-612 started phase I clinical trials in Taiwan.[4]

In January 2021, UB-612 started phase II clinical trials in Taiwan.[5]

In February 2021, UB-612 started phase II/III clinical trials.[6]

References

  1. ^ a b Liao G (27 June 2021). "Taiwan's second domestic COVID vaccine's midterm performance in phase II trials inferior to local competitor: experts". Taiwan News. Retrieved 8 July 2021.
  2. ^ a b Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A, Vaca L (12 July 2021). "SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants". Frontiers in Immunology. 12: 701501. doi:10.3389/fimmu.2021.701501. PMC 8311925. PMID 34322129.
  3. ^ a b "COVID-19 Vaccine". Vaxxinity. Retrieved 9 October 2021.
  4. ^ Clinical trial number NCT04545749 for "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine" at ClinicalTrials.gov
  5. ^ Clinical trial number NCT04683224 for "A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine" at ClinicalTrials.gov
  6. ^ Clinical trial number NCT04773067 for "A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers " at ClinicalTrials.gov

External links

This page is based on the copyrighted Wikipedia article: UB-612. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.